Clinical Trial Update: Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the combination of Sorafenib and Temozolomide in patients with stage III or stage IV melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Nexavar (Sorafenib)
• Temodar (Temozolomide)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Melanoma (Skin) | Phase 1, Phase 2 | Status: UNKNOWN